UPCC 35218: Phase II Trial of Abemaciclib and Nivolumab for Subjects with Hepatocellular Carcinoma
Enrolling By Invitation
99 years or below
All
Phase
2
27 participants needed
1 Location
Brief description of study
The main purpose of this study is to evaluate the effectiveness of the combination of nivolumab and abemaciclib for the treatment of hepatocellular carcinoma. Other goals of this study are to learn about the side effects that this combination of drugs may cause and to learn more about how these drugs work by studying blood and tissue.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: TBD
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832174
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
